Related posts
Tech and oil decline3 Popular Stocks of the Year, Part 1Wall Street advances, Bay Street pausesThis summary was created by AI, based on 3 opinions in the last 12 months.
BioNTech (BNTX-Q) is a $24 billion German biopharmaceutical company that has recently received approvals for a new uterine cancer treatment and an updated COVID vaccine. The company is trading at low multiples and has a strong return on equity, with growing cash reserves and share buybacks. Analysts recommend placing a stop-loss at $78 and looking to achieve a target price of $137, indicating a potential upside of 31%. Despite the lack of dividend yield, the stock is expected to have strong growth potential in the future.
Provides the key insight into mRNA that underlies the Covid vaccine. The mRNA technology can be developed into therapies that are targeted and safe. They are working on a flu vaccine as well as a cancer vaccine. Their pipeline is vast and the coronavirus vaccine is giving a huge cash hoard to pay for R&D. (Analysts’ price target is $185.00)
BioNTech is a American stock, trading under the symbol BNTX-Q on the NASDAQ (BNTX). It is usually referred to as NASDAQ:BNTX or BNTX-Q
In the last year, 1 stock analyst published opinions about BNTX-Q. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for BioNTech.
BioNTech was recommended as a Top Pick by on . Read the latest stock experts ratings for BioNTech.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
1 stock analyst on Stockchase covered BioNTech In the last year. It is a trending stock that is worth watching.
On 2024-04-22, BioNTech (BNTX-Q) stock closed at a price of $88.01.
This $24 billion German based pharma company has received approvals to continue advancement into a new uterine cancer treatment. It trades at 8x trailing earnings, 1.1x book and supports a 23% ROE. Cash reserves are growing, while stock is bought back. We recommend placing a stop-loss at $78, looking to achieve $137 -- upside potential of 31%. Yield 0%
(Analysts’ price target is $137.07)